Topical Application of 5-Aminolevulinic Acid and its Methylester, Hexylester and Octylester Derivatives: Considerations for Dosimetry in Mouse Skin Model¶

Abstract Ester derivatives of 5-aminolevulinic acid (ALA-esters) have been proposed as alternative drugs for ALA in photodynamic therapy. After topical application of creams containing ALA, ALA methylester (ALA-Me), ALA hexylester (ALA-Hex) and ALA octylester (ALA-Oct) on mouse skin, typical fluorescence excitation and emission spectra of protoporphyrin IX (PpIX) were recorded, exhibiting a similar spectral shape for all the drugs in the range of concentrations (0.5–20%) studied. The accumulation kinetics of PpIX followed nearly a similar profile for all the drug formulations. The fluorescence of PpIX peaked at around 6–12 h of continuous cream application. Nevertheless, some differences in pharmacokinetics were noticed. For ALA cream, the highest PpIX fluorescence was achieved using 20% of ALA in an ointment. Conversely, 10% of ALA-Me and ALA-Hex, but not of ALA-Oct, in the cream was more efficient (P < 0.05) than was 20%. The cream becomes rather fluid when 20% of any of these ALA-esters is used in ointment, whereas 10% and lower concentrations of ALA-esters do not significantly increase fluidity of the cream. The dependence of PpIX accumulation on the concentration of ALA and ALA-ester in the applied cream followed (P < 0.002) kinetics as described by a mathematical model based on the Michaelis–Menten equation for enzymatic processes. Under the present conditions, the PpIX amount in the skin increased by around 50% by the application of ALA-Me, ALA-Hex or ALA-Oct for 4–12 h as compared with ALA for the same period. Observations of the mice under exposure to blue light showed that after 8–24 h of continuous application of ALA, the whole mouse was fluorescent, whereas in the case of ALA-Me, ALA-Hex and ALA-Oct the fluorescence of PpIX was located only at the area of initial cream application. The amount of the active compound in the applied cream necessary to induce 90% of the maximal amount of PpIX was determined for normal mouse skin. Optimal PpIX fluorescence can be attained using around 5% ALA, 10% ALA-Me and 5% ALA-Hex creams during short application times (2–4 h). Topical application of ALA-Oct may not gain optimal PpIX accumulation for short applications (<5 h). For long application times (8–12 h), it seems that around 1% ALA, 4% ALA-Me, 6% ALA-Hex and 16% ALA-Oct can give optimal PpIX fluorescence. But for long application times and high concentrations, systemic effect of ALA applied topically on relatively large areas should be considered.

[1]  H Kerl,et al.  Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas? , 1993, Journal of the American Academy of Dermatology.

[2]  Q. Peng,et al.  Photodynamic Therapy , 1988, Methods in Molecular Biology.

[3]  R. Panizzon,et al.  Photodynamic Therapy of Superficial Basal Cell Carcinomas Using Topical 5-Aminolevulinic Acid in a Nanocolloid Lotion , 1998, Dermatology.

[4]  J. P. Connelly,et al.  Comparison of the Pharmacokinetics and Phototoxicity of Protoporphyrin IX Metabolized from 5-Aminolevulinic Acid and Two Derivatives in Human Skin In Vivo¶ , 2000, Photochemistry and photobiology.

[5]  H Anholt,et al.  Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture. , 1997, Cancer research.

[6]  P Lehmann,et al.  Preferential Relative Porphyrin Enrichment in Solar Keratoses upon Topical Application of ^‐Aminolevulinic Acid Methylester , 1998, Photochemistry and photobiology.

[7]  Willem M. Star,et al.  Protoporphyrin IX Fluorescence Kinetics and Localization after Topical Application of ALA Pentyl Ester and ALA on Hairless Mouse Skin with UVB-Induced Early Skin Cancer , 2000, Photochemistry and photobiology.

[8]  M W Berns,et al.  Dosimetry model for photodynamic therapy with topically administered photosensitizers , 1996, Lasers in surgery and medicine.

[9]  J C Kennedy,et al.  NON‐INVASIVE TECHNIQUE FOR OBTAINING FLUORESCENCE EXCITATION AND EMISSION SPECTRA IN VIVO , 1986, Photochemistry and photobiology.

[10]  H. Gollnick,et al.  Photodynamic Therapy in Dermatology , 2012 .

[11]  R. Anderson,et al.  Topical ALA-photodynamic therapy for the treatment of acne vulgaris. , 2000, The Journal of investigative dermatology.

[12]  A. MacRobert,et al.  Comparative effect of ALA derivatives on protoporphyrin IX production in human and rat skin organ cultures , 1999, British Journal of Cancer.

[13]  M. Carstens,et al.  Neurochemical aspects of porphyria. Studies on the possible neurotoxicity of delta-aminolaevulinic acid. , 1975, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[14]  L. Juillerat-Jeanneret,et al.  5-Aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells. , 2000, Journal of photochemistry and photobiology. B, Biology.

[15]  K. Svanberg,et al.  Laser‐induced fluorescence studies of normal and malignant tumour tissue of rat following intravenous injection of δ‐amino levulinic acid , 1997, Lasers in surgery and medicine.

[16]  J. Kennedy,et al.  CLEARANCE TIMES OF PORPHYRIN DERIVATIVES FROM MICE AS MEASURED BY in vivo FLUORESCENCE SPECTROSCOPY , 1984, Photochemistry and photobiology.

[17]  A Mathematical Evaluation of Dose-dependent PpIX Fluorescence Kinetics In Vivo¶ , 2001 .

[18]  J. Kennedy,et al.  Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): mechanisms and clinical results. , 1996, Journal of clinical laser medicine & surgery.

[19]  Johan Emelian Moan,et al.  Clearance of protoporphyrin IX from mouse skin after topical application of 5-aminolevulinic acid and its methyl ester , 1999, European Conference on Biomedical Optics.

[20]  M. Landthaler,et al.  Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. , 1996, Dermatology.

[21]  Joris Kloek,et al.  Prodrugs of 5‐Aminolevullinic Acid for Photodynamic Therapy , 1996, Photochemistry and photobiology.

[22]  Johan Emelian Moan,et al.  Formation of protoporphyrin IX in mouse skin after topical application of 5-aminolevulinic acid and its methyl esther , 1999, European Conference on Biomedical Optics.

[23]  A. Lamola Fluorescence studies of protoporphyrin. Transport and clearance. , 1982, Acta dermato-venereologica. Supplementum.

[24]  J Moan,et al.  On the pharmacokinetics of topically applied 5‐aminolevulinic acid and two of its esters , 2001, International journal of cancer.

[25]  Joris Kloek,et al.  Derivatives of 5‐Aminolevulinic Acid for Photodynamic Therapy: Enzymatic Conversion into Protoporphyrin , 1998, Photochemistry and photobiology.

[26]  M Landthaler,et al.  PENETRATION POTENCY OF TOPICAL APPLIED δ‐AMINOLEVULINIC ACID FOR PHOTODYNAMIC THERAPY OF BASAL CELL CARCINOMA * , 1994, Photochemistry and photobiology.

[27]  Michele T. Cooper,et al.  Cutaneous phototoxic occurrences in patients receiving Photofrin® , 1990, Lasers in surgery and medicine.

[28]  Q. Peng,et al.  Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. , 2001, Journal of photochemistry and photobiology. B, Biology.

[29]  J Moan,et al.  5‐Aminolevulinic acid‐based photodynamic therapy , 1997, Cancer.

[30]  M. Gray,et al.  Hematoporphyrin derivative for detection and management of cancer , 1967, Cancer.

[31]  Z. Malik,et al.  Destruction of erythroleukaemic cells by photoactivation of endogenous porphyrins. , 1987, British Journal of Cancer.

[32]  J. Moan,et al.  Temperature Effect on Accumulation of Protoporphyrin IX After Topical Application of 5-Aminolevulinic Acid and its Methylester and Hexylester Derivatives in Normal Mouse Skin¶ , 2002, Photochemistry and photobiology.

[33]  D. Souza,et al.  Inhibition of adenylate cyclase activity by 5-aminolevulinic acid in rat and human brain. , 2001, Neurochemistry International.

[34]  L. Guillou,et al.  Fluorescence Photodetection (pd) and Photodynamic Therapy Photodetection of Early Human Bladder Cancer Based on the Fluorescence of 5-aminolaevulinic Acid Hexylester- Induced Protoporphyrin Ix: a Pilot Study , 2022 .

[35]  D. V. Ash,et al.  Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. , 1994, British Journal of Cancer.

[36]  P. Charlesworth,et al.  The use of 5-aminolevulinic acid (ALA) in photodynamic therapy (PDT). , 1993, Journal of photochemistry and photobiology. B, Biology.